Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-03-25 | Phyllis R. Yale Director Since: 2019 Age: 62 Board Committees • Committee on Directors and Corporate Governance ...Phyllis R. Yale received $78,413 total compensation in 2019. |
| 2021-03-25 | Phyllis R. Yale Director Since: 2019Age: 63 Board Committees • Audit Committee • Committee on Directors and Corporate Governance Other Public Boards • DaVita, Inc. Experience •Bain & Company (1982-present); Advisory Partner • Has served in a number of leadership roles and has been a leader in building Bain's healthcare practice Key Skills and Experience • Financial • Risk Management • Healthcare • Academia / Non-Profit Other • Chair of the Board of Blue Cross Blue Shield of Massachusetts • Member of the advisory board of Harvard Business School Healthcare Initiative • Member of the advisory board of the Health Policy and Management Department at the Harvard Chan School of Public Health • Member of the board of The Bridgespan Group • Member of the board of The Trustees of Reservations, a conservation and preservation organization |
| 2022-03-24 | Experience: • Bain & Company (1982-present); Advisory Partner • Has served in a number of leadership roles and has been a leader in building Bain’s healthcare practice. |
| 2023-03-23 | Phyllis R. Yale Director Since: 2019 Age: 65 Board Committees • Audit Committee • Committee on Directors and Corporate Governance Other Public Company Board • DaVita, Inc. |
| 2024-03-28 | Phyllis R. Yale DIRECTOR SINCE: 2019 AGE: 66 BOARD COMMITTEES Audit Committee, Committee on Directors and Corporate Governance ... Director Compensation Table shows $365,000 total compensation. |
| 2025-03-26 | Phyllis R. Yale Director Since: 2019 Age: 67 Board Committees • Audit Committee • Science & Technology Committee |
| Filing Date | Source Excerpt |
|---|---|
| 2017-05-01 | Phyllis R. Yale, 59, has been one of our directors since July 2016. ... Ms. Yale is Chair of the board of directors of Kindred Healthcare, Inc. ... Ms. Yale was appointed to the Compliance Committee on November 1, 2016 and to the Public Policy Committee on January 5, 2017. |
| 2018-04-27 | Phyllis R. Yale, 60, has been one of our directors since July 2016. ... Ms. Yale has a deep knowledge base and experience in several segments of the healthcare industry including corporate strategies, marketing and cost and quality management, as well as mergers and acquisitions. |
| 2019-04-29 | Phyllis R. Yale, 61, has been one of our directors since July 2016. ... Ms. Yale has been an Advisory Partner with Bain & Company, Inc. ... She currently serves as Chair of the board of directors of Blue Cross Blue Shield of Massachusetts. ... Ms. Yale has a deep knowledge base and experience in several segments of the healthcare industry including corporate strategies, marketing and cost and quality management, as well as mergers and acquisitions. |
| 2019-12-06 | Phyllis R. Yale ... 2018 DIRECTOR COMPENSATION TABLE ... Phyllis R. Yale $139,500 Fees Earned ... $95,042 Stock Awards ... $94,047 SSAR Awards ... $328,589 Total |
| 2020-04-27 | Phyllis R. Yale, 62, has been an Advisory Partner with Bain & Company, Inc. ... Committee Service: Compliance and Quality Committee ... 2019 DIRECTOR COMPENSATION TABLE ... Phyllis R. Yale $114,000 fees earned, $166,265 stock awards, total $280,265. |
| 2021-04-23 | Phyllis R. Yale, 63, has been an Advisory Partner with Bain & Company, Inc. ("Bain"), a global management consulting firm, since July 2010. Ms. Yale was a Partner with Bain from 1987 to July 2010, and was a leader in building Bain27s healthcare practice. In her role at Bain, Ms. Yale works with healthcare payors, providers, and medical device companies, and frequently advises the world27s leading private equity firms on their investments in the healthcare sector. She has served as a member of the board of directors of several public and private companies in the healthcare sector, and since November 2019 has served as a member of the Board of Directors of Bristol-Myers. Ms. Yale previously served as Chair of the Board of Directors of Kindred and Chair of Blue Cross Blue Shield of Massachusetts, and has been on the board of directors of various other public, non-profit and privately held corporations. Ms. Yale has a deep knowledge base and experience in several aspects of the healthcare industry, including corporate strategies, marketing and cost and quality management, as well as mergers and acquisitions. |
| 2022-04-25 | Phyllis R. Yale, 64, has been an Advisory Partner with Bain & Company, Inc. ("Bain"), a global management consulting firm, since July 2010. Ms. Yale was a Partner with Bain from 1987 to July 2010, and was a leader in building Bain’s healthcare practice. In her role at Bain, Ms. Yale works with healthcare payors, providers, and medical device companies, and frequently advises the world’s leading private equity firms on their investments in the healthcare sector. She has served as a member of the board of directors of several public and private companies in the healthcare sector, and since November 2019 has served as a member of the Board of Directors of Bristol-Myers Squibb Company, a global biopharmaceutical company. Ms. Yale previously served as Chair of the Board of Directors of Kindred and Chair of Blue Cross Blue Shield of Massachusetts. Ms. Yale has a deep knowledge base in the U.S. healthcare sector and has experience in many aspects of the healthcare industry, including corporate strategies, marketing and cost and quality management, as well as mergers and acquisitions. |
| 2023-04-25 | Phyllis R. Yale, 65, has been an Advisory Partner with Bain & Company, Inc. (“Bain”), a global management consulting firm, since July 2010. Ms. Yale was a Partner with Bain from 1987 to July 2010, and was a leader in building Bain’s healthcare practice. In her role at Bain, Ms. Yale works with healthcare payors, providers, and medical device companies, and frequently advises the world’s leading private equity firms on their investments in the healthcare sector. She has served as a member of the board of directors of several public and private companies in the healthcare sector, and since November 2019 has served as a member of the Board of Directors of Bristol-Myers Squibb Company, a global biopharmaceutical company, and since 2014 has served as a member of the Board of Directors of Blue Cross Blue Shield of Massachusetts ("BCBS MA"). Ms. Yale previously served as Chair of the BCBS MA Board of Directors from 2014 to 2019 and Chair of the Board of Directors of Kindred Healthcare, Inc. from 2010 to 2018. Ms. Yale has a deep knowledge base in the U.S. healthcare sector and has experience in many aspects of the healthcare industry, including corporate strategies, marketing and cost and quality management, as well as mergers and acquisitions. |
| 2024-04-26 | Phyllis R. Yale, 66, has been an Advisory Partner with Bain & Company, Inc. (“Bain”), a global management consulting firm, since July 2010. Ms. Yale was a Partner with Bain from 1987 to July 2010, and a leader in building Bain’s healthcare practice. In her role at Bain, Ms. Yale works with healthcare payors, providers, and medical device companies, and frequently advises the world’s leading private equity firms on their investments in the healthcare sector. She has served as a member of the board of directors of several public and private companies in the healthcare sector, and since November 2019 has served as a member of the Board of Directors of Bristol-Myers Squibb Company, a global biopharmaceutical company, and since 2014 has served as a member of the Board of Directors of Blue Cross Blue Shield of Massachusetts ("BCBS MA"). Ms. Yale previously served as Chair of the BCBS MA Board of Directors from 2014 to 2019 and Chair of the Board of Directors of Kindred Healthcare, Inc. from 2010 to 2018. Ms. Yale has a deep knowledge base in the U.S. healthcare sector and has experience in many aspects of the healthcare industry, including corporate strategies, marketing and cost and quality management, as well as mergers and acquisitions. |
Data sourced from SEC filings. Last updated: 2026-02-03